low density lipoprotein receptor class A domain containing 1Genealiases: []
Q-omics provides the consensus-scored LDLRAD1 profile across patient tissues and cancer cell-line models. LDLRAD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LDLRAD1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LDLRAD1 RNA expression shows 12,545 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where LDLRAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDLRAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDLRAD1 survival associations across molecular data types. LDLRAD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDLRAD1 RNA expression–survival associations across cancer types. High LDLRAD1 expression shows unfavorable associations in KIRP, KIRC, THCA and KICH, but favorable associations in HNSC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LDLRAD1 RNA expression.
This table summarizes LDLRAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LDLRAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDLRAD1 shows lower tumor expression in KIRC, LUAD and LUSC and higher tumor expression in LIHC, COAD and BRCA. The KIRC box plot shows higher LDLRAD1 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p < 0.001).
This table shows molecular features associated with LDLRAD1 in patient tissues and cancer cell lines. In patient samples, LDLRAD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LDLRAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BREAST.
